EA200800742A1 - METHOD OF INCREASING THE PERIOD OF SEMI-EXTRACTING OF DIINCRETATE ISOSORBIDE DURING CORONAR FAILURE IN EXPERIMENT - Google Patents

METHOD OF INCREASING THE PERIOD OF SEMI-EXTRACTING OF DIINCRETATE ISOSORBIDE DURING CORONAR FAILURE IN EXPERIMENT

Info

Publication number
EA200800742A1
EA200800742A1 EA200800742A EA200800742A EA200800742A1 EA 200800742 A1 EA200800742 A1 EA 200800742A1 EA 200800742 A EA200800742 A EA 200800742A EA 200800742 A EA200800742 A EA 200800742A EA 200800742 A1 EA200800742 A1 EA 200800742A1
Authority
EA
Eurasian Patent Office
Prior art keywords
experiment
isosorbide
increasing
diincretate
coronar
Prior art date
Application number
EA200800742A
Other languages
Russian (ru)
Other versions
EA017580B1 (en
Inventor
Алмагуль Тулеуовна Маншарипова
Алмас Кенесбаевич Бегдуллаев
Али Ахсан
Original Assignee
Тоо "Казнаномед"
Ао "Национальный Инновационный Фонд"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тоо "Казнаномед", Ао "Национальный Инновационный Фонд" filed Critical Тоо "Казнаномед"
Priority to EA200800742A priority Critical patent/EA017580B1/en
Publication of EA200800742A1 publication Critical patent/EA200800742A1/en
Publication of EA017580B1 publication Critical patent/EA017580B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Способ заключается в увеличении периода полувыведения изосорбида динитрата при коронарной недостаточности в эксперименте путем нанесения мицеллярной формы изосорбида динитрата на грудную клетку из расчета 1 мг/кг массы тела. При введении изосорбида динитрата в виде инъекций период полувыведения составил 0,52 ч, а при введении в виде мицеллярной формы - 8,2 ч, что является свидетельством увеличения периода полувыведения изосорбида динитратаThe method consists in increasing the half-life of isosorbide dinitrate for coronary insufficiency in the experiment by applying the micellar form of isosorbid dinitrate on the chest at the rate of 1 mg / kg body weight. With the introduction of isosorbide dinitrate as an injection, the half-life was 0.52 hours, and when administered as a micellar form, it was 8.2 hours, which is evidence of an increase in the half-life of isosorbide dinitrate

EA200800742A 2008-02-15 2008-02-15 Method for increasing period of isosorbide dinitrate partial ejection in coronary insufficiency EA017580B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA200800742A EA017580B1 (en) 2008-02-15 2008-02-15 Method for increasing period of isosorbide dinitrate partial ejection in coronary insufficiency

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA200800742A EA017580B1 (en) 2008-02-15 2008-02-15 Method for increasing period of isosorbide dinitrate partial ejection in coronary insufficiency

Publications (2)

Publication Number Publication Date
EA200800742A1 true EA200800742A1 (en) 2009-10-30
EA017580B1 EA017580B1 (en) 2013-01-30

Family

ID=41353733

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800742A EA017580B1 (en) 2008-02-15 2008-02-15 Method for increasing period of isosorbide dinitrate partial ejection in coronary insufficiency

Country Status (1)

Country Link
EA (1) EA017580B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748626B1 (en) * 1994-02-28 2001-08-16 Teijin Limited Patch containing isosorbide dinitrate and prepared by using adhesive mixture
RU2267318C1 (en) * 2004-05-25 2006-01-10 Закрытое акционерное общество "ФАРМАПЭК" Prolonged antianginal preparation of isosorbide dinitrate and method for its obtaining

Also Published As

Publication number Publication date
EA017580B1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
CL2013001558A1 (en) The use of s1p receptor modulating or agonist compounds to decrease heart rate by approximately 2 beats / minute; method to reduce, prevent or limit a negative chronotropic effect; a pharmaceutical kit
MX2023011456A (en) Methods of reducing the risk of cardiovascular events in a subject.
AR047993A1 (en) PHARMACEUTICAL COMPOSITION THAT PIMOBENDAN INCLUDES
EA200970237A1 (en) APPLICATION TENEKTPLAZY FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
HRP20171648T1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
EA201270570A1 (en) COMBINED THERAPY OF CANCER DISEASES USING HSP90 INHIBITOR COMPOUNDS
PE20141906A1 (en) ESKETAMINE FOR THE TREATMENT OF DEPRESSION REFRACTORY TO TREATMENT OR RESISTANT TO TREATMENT
EA201100969A1 (en) SALT FORMS OF ORGANIC COMPOUND
PH12014502217A1 (en) Methods for improving diaphragm function
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX2009003958A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof.
MX345440B (en) Method for chemically modifying the internal region of a hair shaft.
PA8794401A1 (en) 6-PHENYLNICOTINIC ACIDS SUBSTITUTED AND ITS USE
CL2013000580A1 (en) Method of muscle regeneration or repair comprising administering a range retinoic acid receptor antagonist (rary); method for the induction or stimulation of myogenic differentiation of stem cells; composition comprising mesenchymal stem cells; pharmaceutical composition; kit
CL2012001961A1 (en) Method for treating a disease or disorder in which levels of stress hormones increase and / or levels of androgen hormones decrease, in which a substituted pyrrolo- [1,2-c] -imidazol-benzyl compound is administered; its use in heart failure, among others; and substituted pyrrolo- [1,2-c] -imidazol-benzyl compounds.
GEP20146080B (en) Chromone derivatives, method of their preparation and therapeutic applications
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
ES2673406T3 (en) Alpha-derivatives of cis-monounsaturated fatty acids for use as medications in the treatment of diabetes
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
MX2014001823A (en) Combinations of corroles and statins.
MX2012001107A (en) Amide derivative.
EA200800742A1 (en) METHOD OF INCREASING THE PERIOD OF SEMI-EXTRACTING OF DIINCRETATE ISOSORBIDE DURING CORONAR FAILURE IN EXPERIMENT
EA200800743A1 (en) METHOD OF INCREASING THE CONTENT OF ACTIVE METABOLITES OF DINITRATE ISOSORBIDE IN THE BLOOD DURING CORONARY FAILURE IN EXPERIMENT
EA200800741A1 (en) METHOD OF INTRODUCTION OF ISOCHORBIDE DINITRATE DURING CORONARY FAILURE IN EXPERIMENT
UA125971U (en) METHOD OF STRENGTHENING ANTI-INFLAMMATORY ACTION OF Meloxicam

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU